Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in…
How Ireland became dependent on big pharma - and the risks ahead
In just 50 years, Ireland has become the world's third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland's GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid…
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or 'the Company') (Nasdaq:…
Bayer Weighs U.S. Pharma Expansion as Turnaround Picks Up Speed
is looking at expanding its pharmaceutical manufacturing footprint in the U.S., the head of its pharma unit said, as the business turns to the world's largest drug market to fuel a turnaround. The pharma division of the German conglomerate is…
Mirum Pharma (MIRM) Earnings Call Transcript
Tuesday, Nov. 4, 2025 at 8 a.m. ET Chief Executive Officer — Christopher Peetz President and Chief Operating Officer — Peter Radovich Chief Medical Officer — Joanne M. Quan Chief Financial Officer — Eric Bjerkholt Need a…
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that it intends to complete an offering of a debenture of the Company (the…
Strategic Partnerships at PHARMAP 2026 - Big Pharma's Shift Toward CDMOs and CMOs
Outsourcing is no longer just about cost reduction. Pharma companies now seek strategic partnerships, agility and innovation, focusing on long-term cooperations, shared risk and early CMO involvement. Underscoring this trend, Bora Pharmaceuticals…
Marksans Pharma gets USFDA nod for generic Benzonatate capsules
Marksans Pharma Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Benzonatate capsules indicated for treatment of persistent cough, bronchitis, pneumonia or other lung infections. The…
Analysis: Middle East war disrupts pharma air routes, risks cancer drugs supply
War snarls critical drug deliveries to Gulf Drugmakers reroute cargo as Dubai, Doha hubs are hit Cancer drugs face higher supply risk No major shortages yet, industry says Hospitals could face pressure within weeks LONDON — War in the Middle…
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Lilly and Novo Show How AI Is Rewiring Big Pharma
Eli Lilly signed a $2.75 billion partnership with Hong Kong-based AI drug discovery firm Insilico Medicine, giving it exclusive rights to develop and commercialize drugs built on Insilico's Pharma.ai platform. As reported by PYMNTS on Monday (March…
HC Wainwright Lifts Earnings Estimates for Spyglass Pharma
Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Spyglass Pharma in a report issued on Monday, March 30th. HC Wainwright analyst Y. Chen now expects that the…
Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?
Apellis Pharmaceuticals (APLS) shares soared on Tuesday after Biogen (BIIB) signed a definitive agreement to acquire the biopharmaceutical firm for about $5.6 billion in cash. Biogen's proposal values APLS shares at $41 each, representing a…
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of 'Moderate Buy' from Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been assigned an average rating of 'Moderate Buy' from the twenty-four research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock…
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX
J. Safra Sarasin Holding AG acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 90,035 shares of the…
Receive a Daily briefing on Pharma Industry News
Get Started